TRANSCAN-3> It's a collaborative network of ministries, national and regional funding agencies as well as research councils with programmes in translational cancer research. ## The Project [TRANSCAN-3](https://transcan.eu/the-project/transcan-3.kl): Joining efforts to make a difference in the fight against cancer ## Calls for Proposals [Joint Call (JTC 2021)](https://transcan.eu/funding/calls/next-generation-cancer-immunotherapy-targeting-the-tumour-microenvironment.kl): TRANSCAN-3 first Joint Transnational Call co-funded by the European Commission: "Next generation cancer immunotherapy: targeting the tumour microenvironment" [Joint Call (JTC 2017)](https://transcan.eu/funding/calls/fourth-joint-transnational-call-jtc-2017-.kl): Call for proposals on “Translational research on rare cancers” ## Funded projects [BRCAddict](https://transcan.eu/output-results/funded-projects/brcaddict.kl): Harnessing BRCAness as a therapeutic target in high-risk pediatric solid tumors   ## Success Stories [ONTHETRRAC](https://transcan.eu/output-results/success-stories/era-net-transcan-3-sustained-collaboration-of-national-and-regional-programmes-in-cancer-research.kl):  Overcoming Neuroblastoma Tumour HETerogeneity, Resistanceand RecurrAnCe - ONTHETRRAC ## Latest News [TRANSCAN-3 launches its first transnational call for research proposals (JTC 2021)](https://transcan.eu/news-and-resources/updates/first-joint-transnational-call-for-research-proposals-jtc-2021-.kl): On April 6th 2021, ERA-NET TRANSCAN-3 launched its first Joint Transnational Call co-funded by the European Commission (JTC 2021) with the support of 28 funding organisations from 19 countries on the ... [TRANSCAN-3 - International Networking Event focusing on JTC 2021](https://transcan.eu/news-and-resources/updates/era-net-transcan-3-joint-transnational-call-2021-international-networking-event.kl): The event was organized by TÜBİTAK within the scope of Turkey in Horizon 2020 Phase-II Project, with the support of co-organizers FCAECC, FICYT and the TRANSCAN-3 network     [Other developments and initiatives in transnational cancer research](https://transcan.eu/news-and-resources/updates/other-developments-and-initiatives-in-transnational-cancer-research.kl): The TRANSCAN-3 kick-off meeting held in April 2021 included a round table to comment on important events and activities related to translational cancer research within each organisation/region/country. ... ## Funding Opportunities [Investing in Cancer Research](https://transcan.eu/funding/calls.kl): TRANSCAN-3 aims at coordinating investment in identified common priority areas of cancer research that contributes to significant advances in cancer prevention, detection, diagnosis, treatment, and quality of life for patients. ## Partners [Partners](https://transcan.eu/the-project/partners/partners.kl): At TRANSCAN-3 we are working together to keep the fight against cancer to the high priority status it deserves.  ## Calls for Proposals [Joint Call (JTC 2016)](https://transcan.eu/funding/calls/third-joint-transnational-call-jtc-2016-.kl): Call for proposals on “Minimally and non-invasive methods for early detection and/or progression of cancer”   [Joint Call (JTC 2015)](https://transcan.eu/funding/calls/second-joint-transnational-call-jtc-2015-.kl): Call for proposals on “Immunology and immunotherapy of cancer: strengthening the translational aspects” [Joint Call (JTC 2014)](https://transcan.eu/funding/calls/joint-transnational-call-jtc-2014-.kl): Call for proposals co-funded by the European Commission on "Translational research on human tumour heterogeneity to overcome recurrence and resistance to therapy" [Joint Call (JTC 2013)](https://transcan.eu/funding/calls/joint-transnational-call-jtc-2013-.kl): Call for proposals on "Translational research on tertiary prevention in cancer patients" [Joint Call (JTC 2012)](https://transcan.eu/funding/calls/joint-transnational-call-jtc-2012-.kl): Call for proposals on “Translational research on primary and secondary prevention of cancer”   [Joint Call (JTC 2011)](https://transcan.eu/funding/calls/joint-transnational-call-jtc-2011-.kl): Call for proposals on "Validation of biomarkers for personalised cancer medicine" ## Funded projects [ERANET-PLL](https://transcan.eu/output-results/funded-projects/eranet-pll.kl): Implementation of (epi)genetic and metabolic networks in the targeting of T-cell prolymphocytic leukemia [Euro MDS](https://transcan.eu/output-results/funded-projects/euro-mds.kl): An integrated European platform to conduct translational studies in myelodysplastic syndromes based on the EuroBloodNet infrastructure [EuroTCLym](https://transcan.eu/output-results/funded-projects/eurotclym.kl): Translational Research in Peripheral T-Cell Lymphomas: from characterization to novel targets [LIQUIDHOPE](https://transcan.eu/output-results/funded-projects/liquidhope.kl): Advancing liquid biopsies for monitoring and personalized treatment of children with neuroblastomas [MOLCARUTUC](https://transcan.eu/output-results/funded-projects/molcarutuc.kl): Comprehensive genomic characterization of upper urinary tract urothelial carcinoma and paired bladder recurrences [NExT](https://transcan.eu/output-results/funded-projects/next.kl): Establishing an algorithm for the early diagnosis and follow-up of patients with pancreatic neuroendocrine tumors [PMTR-pNET](https://transcan.eu/output-results/funded-projects/pmtr-pnet.kl): Predictive models of therapy response in pancreatic neuroendocrine tumors [PREDICt](https://transcan.eu/output-results/funded-projects/predict.kl): Profiling radioREsistant Differentiated thyroid Cancer: genes, immunity, cancer stem cells and epithelial-mesenchymal transition [Quant-ALL](https://transcan.eu/output-results/funded-projects/quant-all.kl): Automated, absolute quantification of MRD in ALL patients by droplet microfluidics, single DNA copy barcoding and IG/TR amplicon NGS [ROCSANbio](https://transcan.eu/output-results/funded-projects/rocsanbio.kl): Anti-PD1 and Niraparib (PARPi) combination therapy in gynae carcinosarcoma: Identification of response-predictive biomarkers and resistance mechanisms [TOPMESO](https://transcan.eu/output-results/funded-projects/topmeso.kl): A TranslatiOnal Platform for de-orphaning malignant pleural MESOthelioma [ABC-Cancer](https://transcan.eu/output-results/funded-projects/abc-cancer.kl): Airborne biomarkers for colorectal cancers [BioEndoCar](https://transcan.eu/output-results/funded-projects/bioendocar.kl): Biomarkers for diagnosis and prognosis of endometrial carcinoma [CLEARLY](https://transcan.eu/output-results/funded-projects/clearly.kl): Validation of multiparametric models and Circulating and imaging biomarkers to improve Lung cancer EARLY detection [ESCEND](https://transcan.eu/output-results/funded-projects/escend.kl): Detection of early esophageal cancer by near-infrared fluorescence molecular endoscopy [GLIOMA-PRD](https://transcan.eu/output-results/funded-projects/glioma-prd.kl): Multi-parametric analysis of the evolution and progression of low grade glioma [iMMunocell](https://transcan.eu/output-results/funded-projects/immunocell.kl): Single-cell immunophenotypic and transcriptomic profiling for minimally-invasive detection of early multiple myeloma [NIRBTEST](https://transcan.eu/output-results/funded-projects/nirbtest.kl): New strategies to detect cancers in carriers of mutations in RB1: blood tests based on tumor-educated platelets, or extracellular vesicles [NOVEL](https://transcan.eu/output-results/funded-projects/novel.kl): Employing NGS technology for improved, non-invasive early detection, staging and prediction of progression in lymphoma patients [PROLIPSY](https://transcan.eu/output-results/funded-projects/prolipsy.kl): Early detection of prostate cancer by liquid biopsies [PROSCANEXO](https://transcan.eu/output-results/funded-projects/proscanexo.kl): Exploitation of extracellular vesicles for precision diagnostics of prostate cancer [R.E.ST.ING](https://transcan.eu/output-results/funded-projects/r-e-st-ing.kl): Non-invasive prognostic markers for Resected Early-STage NSCLC: role of circulatING and exosomal miRNAs and free circulating DNA [SCRAtCH](https://transcan.eu/output-results/funded-projects/scratch.kl): Microbiota-based SCReening of Anal Cancer in HIV-infected individuals [THRuST](https://transcan.eu/output-results/funded-projects/thrust.kl): Early detection of relapses in stage III colon cancer patients by longitudinally following a personalized molecular signature from a a blood test: THRuST [TRANSCALL-2](https://transcan.eu/output-results/funded-projects/transcall-2.kl): Integration of genetic biomarkers and early minimal residual disease to improve risk stratification and cure in childhood Acute Lymphoblastic Leukemia [DIgesT](https://transcan.eu/output-results/funded-projects/digest.kl): Impact of dietary intervention on tumor immunity [EPICA](https://transcan.eu/output-results/funded-projects/epica.kl): Dual epigenetic targeting and immunotherapy to fight against cancer [HEPAMUT](https://transcan.eu/output-results/funded-projects/hepamut.kl): Mutated neo-antigens in hepatocellular carcinoma [IMMUNOGLIO](https://transcan.eu/output-results/funded-projects/immunoglio.kl): Deciphering immune response against glioblastoma to find new targets [IMMUSPHINX](https://transcan.eu/output-results/funded-projects/immusphinx.kl): Targeting sphingolipid metabolism to improve anti-melanoma immunotherapy [ARREST](https://transcan.eu/output-results/funded-projects/arrest.kl): Approaching recurrence and resistance mechanisms in esophagogastric adenocarcinomas from the prospective MEMORI trial [BeFIT](https://transcan.eu/output-results/funded-projects/befit.kl): Patient-derived models for intratumor functional heterogeneity and its implications for personalized medicine [CCE Breast](https://transcan.eu/output-results/funded-projects/cce.kl): Breast    Clinical impact of intratumor heterogeneity in metastatic breast cancer [CEVIR](https://transcan.eu/output-results/funded-projects/cevir.kl): Cancer evolution and identification of relapse-initiating cells [DRAMA](https://transcan.eu/output-results/funded-projects/drama.kl): Defeating Recurrence and resistance in AML:Multigenomic Approaches to analyse heterogeneity [FIRE-CLL](https://transcan.eu/output-results/funded-projects/fire-cll.kl): Fighting Resistance in CLL [GCH-CLL](https://transcan.eu/output-results/funded-projects/gch-cll.kl): Genetic and cellular intratumor heterogeneity as predictor of chronic lymphocytic leukemia outcome and treatment resistance [HetMet](https://transcan.eu/output-results/funded-projects/hetmet.kl): Intratumour heterogeneity, clonal selection and metastatic propensity in breast cancer [INTRACOLOR](https://transcan.eu/output-results/funded-projects/intracolor.kl): Evolution of resistant clones to novel target-directed drugs in colorectal tumors. A genetic and epigenetic study of intratumoral  heterogeneity dynamics [IntraMMclo](https://transcan.eu/output-results/funded-projects/intrammclo.kl): Multiple myeloma intra-clonal heterogeneity: evolution and implications of targeted therapy [ITEM](https://transcan.eu/output-results/funded-projects/item.kl): Dissecting phenotypic heterogeneity of human melanoma: building a rationale for active immunotherapies overcoming immunologically-induced dedifferentiation [ONTHETRRAC](https://transcan.eu/output-results/funded-projects/onthetrrac.kl):  Overcoming Neuroblastoma Tumour HETerogeneity, Resistance and RecurrAnCe [PROMETOV](https://transcan.eu/output-results/funded-projects/prometov.kl): Proteogenomic and targeted metabolomic analysis of ovarian cancer heterogeneity and its contribution to recurrence and therapy resistance [TACTIC](https://transcan.eu/output-results/funded-projects/tactic.kl): TArgeting Colon Tumor Initiating Cell heterogeneity [TH4RESPONS](https://transcan.eu/output-results/funded-projects/th4respons.kl): Clinical utility of tumour heterogeneity in triple negative breast cancer and high-grade serous ovarian carcinoma for prediction of therapy response [TORPEDO](https://transcan.eu/output-results/funded-projects/torpedo.kl): Targeting Of Resistance in PEDiatric Oncology [ASAMET](https://transcan.eu/output-results/funded-projects/asamet.kl): A randomized, 2x2 biomarker prevention trial of low-dose aspirin and metformin in colon cancer patients [ATRTPepVac](https://transcan.eu/output-results/funded-projects/atrtpepvac.kl): Exploiting the peptidome of atypical teratoid/rhabdoid tumors - characterization of novel tumor-associated antigens for immunotherapy in order to maintain long-term remissions [Bio-PaC](https://transcan.eu/output-results/funded-projects/bio-pac.kl): Biomarkers of tumor recurrence in pancreatic cancer [BREMIR](https://transcan.eu/output-results/funded-projects/bremir.kl): MicroRNAs methylation and expression profiling for identification of breast cancer patients at high risk to develop distant metastases [DietINT](https://transcan.eu/output-results/funded-projects/dietint.kl): A randomized phase II study for tertiary prevention of squamocellular cancer of head and neck (SCCHN) with a dietary intervention [FOCUS](https://transcan.eu/output-results/funded-projects/focus.kl): Biomarkers related to folate-dependent one-carbon metabolism in CRC recurrence and survival [GENMEL](https://transcan.eu/output-results/funded-projects/genmel.kl): Identification of genetic markers involved in development of metastases and second cancers in melanoma [HIGHCARE](https://transcan.eu/output-results/funded-projects/highcare.kl): High resolution project on prognosis and CARE of cancer patients [IMMUNOSCOR](https://transcan.eu/output-results/funded-projects/immunoscor.kl): Integrative cancer-immunology and Immunoscore for cancer classification and immunotherapies [MetBreCS](https://transcan.eu/output-results/funded-projects/metbrecs.kl): A randomized placebo controlled phase II study with Metformin in metabolic-unbalanced breast cancer survivors at higher risk for recurrence  [EpiMARK](https://transcan.eu/output-results/funded-projects/epimark.kl): An integrated approach for epigenetic risk assessment and biomarker development for breast cancer in prospective cohorts / Identifying early epigenetic predictors of breast cancer risk and their etiology ... [FAMILIAL CANCER](https://transcan.eu/output-results/funded-projects/familial-cancer.kl): Cancer prevention through improved familial risk assessment and gene discovery [HLALOSS](https://transcan.eu/output-results/funded-projects/hlaloss.kl): New technologies for early detection of HLA loss leukemia relapse after allogeneic hematopoietic stem cell transplantation, and identification of relevant risk factors [Ma.Tr.OC](https://transcan.eu/output-results/funded-projects/ma-tr-oc.kl): Identification of molecular therapeutic targets and diagnostic/prognostic biomarkers for Malignant Transformation of Osteochondromas [MesaCapp](https://transcan.eu/output-results/funded-projects/mesacapp.kl): Mesalamine for Colorectal Cancer Prevention Program in Lynch syndrome [MetaboCCC](https://transcan.eu/output-results/funded-projects/metaboccc.kl): Metabolomic profiles throughout the continuum of colorectal cancer [NanoEFEct](https://transcan.eu/output-results/funded-projects/nanoefect.kl): Nanoparticle-Enhanced molecular Fluorescence-Endoscopy for detection of early-stage colorectal adenocarcinomas [PREDICT](https://transcan.eu/output-results/funded-projects/predict_1.kl): Personalized prevention of colorectal neoplasia by use of genetic variability for the prediction of efficacy and toxicity of treatment with COX-2 inhibitors and aspirin [TRANsIBCCS](https://transcan.eu/output-results/funded-projects/transibccs.kl): Development of a Comprehensive Risk Prediction Model for BRCA1 and BRCA2 mutation carriers [Triage-MDS](https://transcan.eu/output-results/funded-projects/triage-mds.kl): TRanslational Implementation of Genetic Evidence in the management of MDS [BioRaRE](https://transcan.eu/output-results/funded-projects/bio-rare.kl): K-RAS mutations and DNA repair function in NSCLC [CTC-SCAN](https://transcan.eu/output-results/funded-projects/ctc-scan.kl): Circulating Tumor Cells as Biomarker for Minimal Residual Disease in Prostate Cancer [ET-FES](https://transcan.eu/output-results/funded-projects/et-fes.kl): Early prediction of efficacy of endocrine therapy in breast cancer: pilot study and validation with 18F Fluoroestradiol (FES) PET/CT [GRAN-T-MTC](https://transcan.eu/output-results/funded-projects/gran-t-mtc.kl): Phase I clinical trial using a novel CCK-2/gastrin receptor-localizing radiolabelled peptide probe for personalized diagnosis and therapy of patiens with progressive or metastatic medullary thyroid ca ... [HAPLO-IMMUNE](https://transcan.eu/output-results/funded-projects/haplo-immune.kl): Validation of immune biomarkers predictive of clinical outcome after HLA-haploidentical hematopoietic stem cell transplantation for acute leukemia [ImPECT](https://transcan.eu/output-results/funded-projects/impect.kl): Immune Cells as Predictors for Early Diagnosis and Chemotherapy Toxicity in Ovarian Cancer [PROVABES](https://transcan.eu/output-results/funded-projects/provabes.kl): PROspective VAlidation of Biomarkers in Ewing Sarcoma for personalised translational medicine [TRANSCALL](https://transcan.eu/output-results/funded-projects/transcall.kl): Validation of the impact of genetic aberrations and host genetic variation in childhood acute lymphoblastic leukemia for integration into clinical practice [UGI1](https://transcan.eu/output-results/funded-projects/ugi1.kl): CD3 and CD20 lymphocytes infiltration to predict chemosensitivity in patients with triple negative breast cancer [VALPRAXIN](https://transcan.eu/output-results/funded-projects/valpraxin.kl): Validation of Aprataxin as a biomarker of response to Topoisomerase I inhibitors in cancer patient ## Partner portal [Login to our restricted area](https://transcan.eu/partner-portal/login-to-our-restricted-area.kl): ## Output [Funded Research Output](https://transcan.eu/output-results/output.kl): Since  2011, the TRANSCAN network has invested in 126 transnational research projects involving nearly 628 researchers from over 20 countries. ## Fact and figures [Results of JTC 2017 funded projects](https://transcan.eu/output-results/fact-and-figures/results-of-jtc-2017-funded-projects.kl): Overview of the call on "Translational research on Rare Cancers"  ## Objectives [Project Objectives](https://transcan.eu/the-project/objectives/project-objectives.kl): Consistent with TRANSCAN-3's high ambitions, the consortium sets leading-edge objectives. ## At a glance [At a glance](https://transcan.eu/the-project/at-a-glance/at-glance.kl): Translational cancer research is key for addressing, understanding and preventing cancer, a worldwide health concern despite the continuous advancement of research and treatment approaches. ## Latest News [TRANSCAN-3 Kick-off Meeting](https://transcan.eu/news-and-resources/updates/transcan-3-kick-off-meeting.kl): Virtual,  27-28 April 2021 ## Expected Impact [Expected Impact](https://transcan.eu/the-project/expected-impact/expected-impact.kl): Identification of common research and innovation priorities The identification of common research and innovation priorities is a key element in the TRANSCAN-3 decision-making process to select the topics for the joint transnational calls. ## Success Stories [TH4RESPONS](https://transcan.eu/output-results/success-stories/th4respons.kl): Clinical utility of tumour heterogeneity in triple negative breast cancer and high-grade serous ovarian carcinoma for prediction of therapy response - TH4RESPONS ## Newsletters [Newsletters](https://transcan.eu/news-and-resources/newsletters/archivio.kl): The TRANSCAN-3 newsletter provides periodical updates on the key activities of the project. ## Funded projects [RE-VOLU-TION](https://transcan.eu/output-results/funded-projects/revolution.kl): Prediction of Nivolumab action in metastatic renal cancer patients: Treg function, tumoral access and NK interaction as predictive biomarkers of immunotherapy [Microther](https://transcan.eu/output-results/funded-projects/microther.kl): Improving immunotherapy of solid tumors by targeting the immunosuppressive tumor microenvironment: from pre-clinical proof-of-concept to the development of phase Ib study ## Latest News [Interview with Prof. Walter Ricciardi](https://transcan.eu/news-and-resources/updates/interview-with-prof-walter-ricciardi.kl): Chair of the EU Cancer Mission Board. Prof. Walter Ricciardi provided insights on the EU Cancer Mission and the current and future synergies with TRANSCAN-3.  ## Fact and figures [Overview of the results of the 2011-2017 joint calls](https://transcan.eu/output-results/fact-and-figures/era-net-tanscan-2-.kl): ERA-NET TRANSCAN-2: ALIGNING NATIONAL/ REGIONAL TRANSLATIONAL CANCER RESEARCH PROGRAMMES AND ACTIVITIES     TRANSCAN and TRANSCAN-2 Research Funding Overview of the 2011-2017 Joint Transnational Calls’ Results TRANSNATIONAL APPROACH to translational cancer research since 2011 Over a period of 11 years, a total funding of €85. ## Contact us [Contact us](https://transcan.eu/the-project/contact-us/contact-us.kl): Project Coordinator  Dr. Giusi CONDORELLI Ministero della Salute  (IT-MOH) Viale Giorgio Ribotta, 5 00144 - Rome, Italy Project Manager Dr. ## Fact and figures [Results of JTC 2016 funded projects](https://transcan.eu/output-results/fact-and-figures/results-of-jtc-2016-funded-projects.kl): Overview of the call on “Minimally and non-invasive methods for early detection and/or progression of cancer” [Results of JTC 2015 funded projects](https://transcan.eu/output-results/fact-and-figures/results-of-jtc-2015-funded-projects.kl): Overview of the call on “Immunology and immunotherapy of cancer: strengthening the translational aspects” [Results of JTC 2014 funded projects](https://transcan.eu/output-results/fact-and-figures/results-of-jtc-2014-funded-projects.kl): Overview of the EC cofunded call on   “Translational research on human tumour heterogeneity to overcome recurrence and resistance to therapy” ## Legal Notice [Legal Notice](https://transcan.eu/legal-notice/legal-notice.kl): Editor TRANSCAN-3 Network Coordination Unit c/o Ministero della Salute DG for Research and Innovation in Healthcare Viale Giorgio Ribotta, 5 – 00144 Rome - Italy Disclaimer The TRANSCAN-3 network makes its best efforts to keep the information on its website timely and accurate. ## Privacy Policy [Privacy Policy](https://transcan.eu/privacy-policy/privacy-policy.kl): Last updated on 05/04/2022 The TRANSCAN-3 data privacy policy complies with the provisions set out in the General Data Protection Regulation (EU) 2016/679. ## Latest News [Launch of the new TRANSCAN-3 website](https://transcan.eu/news-and-resources/updates/launch-of-our-new-transcan-3-website.kl): We are delighted to announce the launch of the new TRANSCAN-3 website. [Pre-announcement: Upcoming Call JTC 2022](https://transcan.eu/news-and-resources/updates/new-funding-opportunity-preannouncement.kl): "Novel translational approaches to tackle the challenges of hard-to-treat cancers from early diagnosis to therapy" ## Calls for Proposals [Joint Call (JTC 2022)](https://transcan.eu/funding/calls/joint-call-jtc-2022-.kl): Call for research proposals on “Novel translational approaches to tackle the challenges of hard-to-treat cancers from early diagnosis to therapy” ## Latest News [TRANSCAN-3 launches its second transnational call for proposals (JTC 2022)](https://transcan.eu/news-and-resources/updates/transcan-3-launches-its-second-transnational-call-for-research-proposals-jtc-2022-.kl): With the support of 24 funding organisations from 17 different countries,  TRANSCAN-3 has launched a call for research proposals on the topic of: ## Funded projects [ANEMONE](https://transcan.eu/output-results/funded-projects/anemone.kl): The ANswer within the microEnvironment: Malignant pleural mesothelioma resistance to Old and NEw drugs [BIALYMP](https://transcan.eu/output-results/funded-projects/bialymp.kl): Bispecific antibodies in Lymphoma: Microenvironmental profiling to predict treatment response and uncover immunogenic resistance mechanisms [CHRYSALIS](https://transcan.eu/output-results/funded-projects/chrysalis.kl): Characterization of stromal and innate lymphoid cell populations involved in immunotherapy resistance in High-Grade Serous Ovarian [IMMOSCAN](https://transcan.eu/output-results/funded-projects/immoscan.kl): The role of IMMune OSteoclasts in CANcer – Implications for therapy [ImmuMet](https://transcan.eu/output-results/funded-projects/immumet.kl): Invigorating immunity against brain metastases in lung and breast cancer patients [iParaCyts](https://transcan.eu/output-results/funded-projects/iparacyts.kl): Understanding and therapeutically exploiting the immunosuppressive paracrine signalling in the tumour microenvironment of metastatic lesions [LipidMac](https://transcan.eu/output-results/funded-projects/lipidmac.kl): Exploiting lipid-laden macrophages to overcome resistance to cancer immunotherapy [PERIMMUNE](https://transcan.eu/output-results/funded-projects/perimmune.kl): Intraperitoneal Immune Modulation for Colorectal Peritoneal Metastases [PIXEL](https://transcan.eu/output-results/funded-projects/pixel.kl): Profiling and functional analysis of the Immune environment of eXtramedullary leukemia rELapses [PREDICO](https://transcan.eu/output-results/funded-projects/predico.kl): Defining Predictive Immunedeterminants of response to neoadjuvant Chemoradiation in Oesophageal adenocarcinoma [Pur-Ther](https://transcan.eu/output-results/funded-projects/pur-ther.kl): New immunotherapies targeting the key purinergic checkpoints in the tumor microenvironment [RISEBrain](https://transcan.eu/output-results/funded-projects/risebrain.kl): Reverting immune suppression to elicit brain metastasis control [SmartCAR-T](https://transcan.eu/output-results/funded-projects/smartcar-t.kl): SmartCAR-T - Reprogramming of the tumor microenvironment with modular engineered CAR-T cells to augment the efficacy of immunotherapy [TALETE](https://transcan.eu/output-results/funded-projects/talete.kl): TArgeting acute myeloid Leukemia immunosuppressive microEnvironment by combined IDO1 inhibiTion and PD-1 blockadE [TANGERINE](https://transcan.eu/output-results/funded-projects/tangerine.kl): Artificial-intelligence-based end-to-end prediction of cancer immunotherapy response [TENACITY](https://transcan.eu/output-results/funded-projects/tenacity.kl): TargEting the Nectin fAmily to boost Cancer ImmuniTY [TRanSLIT](https://transcan.eu/output-results/funded-projects/translit.kl): Targeting ROBOs and SLIT guidance cues in the immune-suppressive stromal context of pancreatic cancer   [TumorOUT](https://transcan.eu/output-results/funded-projects/tumorout.kl): Innovative mRNA vaccine against NSCLC: Designing a platform of targeted polymeric nanoparticles for efficient personalized therapy [UCIPredict](https://transcan.eu/output-results/funded-projects/ucipredict.kl): Circulating tumour microenvironment components as Urothelial Cancer Immunotherapy Response Predictors [MAGNOLIA](https://transcan.eu/output-results/funded-projects/magnolia.kl): MAppinG adaptatioN Of tripLe negative breast cancer microenvironments to ImmunotherApy ## Latest News [Results of the co-funded call JTC 2021](https://transcan.eu/news-and-resources/updates/results-of-the-co-funded-joint-transnational-call-2021.kl): 20 consortia were selected for financing for a total amount of 25.9 million euros. [Interview with Dr. Stefanie Houwaart](https://transcan.eu/news-and-resources/updates/interview-with-dr-stefanie-houwaart.kl): Dr. Stefanie Houwaart is a  member of the Scientific Advisory Board of TRANSCAN-3 and coordinator of patient interests of the German Cancer Aid ## Fact and figures [Results of the EC co-funded call JTC 2021](https://transcan.eu/output-results/fact-and-figures/results-of-the-ec-co-funded-call-jtc-2021.kl): Overview of the co-funded call on "Next generation cancer immunotherapy: targeting the tumour microenvironment" ## Success Stories [An interview with ECR, Dr. Pinar Pir](https://transcan.eu/output-results/success-stories/iparacyts.kl): iParaCyts project: Evaluating the therapeutic potential of immunosuppressive paracrine cytokines in the tumor microenvironment of metastatic lesions  [Meet ECR, Dr. Sheng-Fang Su](https://transcan.eu/output-results/success-stories/meet-ecr-dr-dr-sheng-fang-su.kl): BeFIT project: Patient-derived models for intratumor functional heterogeneity and its implications for personalized medicine  ## Latest News [Preliminary announcement: Upcoming Call 2023](https://transcan.eu/news-and-resources/updates/preannouncement-jtc-2023.kl): "Translational research on cancer epigenetics" ## Calls for Proposals [Joint Call (JTC 2023)](https://transcan.eu/funding/calls/joint-call-jtc-2023-.kl): Call for research proposals: “Translational research on cancer epigenetics” ## Latest News [TRANSCAN-3 launches its third transnational call (JTC 2023)](https://transcan.eu/news-and-resources/updates/transcan-3-launches-its-third-transnational-call-for-proposals-jtc-2023-.kl): With the support of 24 funding organisations from 19 different countries,  TRANSCAN-3 has launched a call for research proposals on the topic of: [JTC 2023 International Info Day and Networking Event](https://transcan.eu/news-and-resources/updates/jtc2023-international-info-day-and-networking-event.kl): This event is organized by TÜBİTAK within the scope of Turkey in Horizon 2020 Phase-II Project, with the support of co-organizers FCAECC, FICYT and the TRANSCAN-3 network.   [Results of the joint transnational call JTC 2022](https://transcan.eu/news-and-resources/updates/results-of-the-joint-transnational-call-jtc-2022.kl): 14 consortia were selected for financing for a total amount of 15.1 million euros. ## Funded projects [ANGELA](https://transcan.eu/output-results/funded-projects/angela.kl): Early detection of esophageal squamous cell carcinoma with the Cytosponge coupled with molecular biomarkers and machine learning [BileCanMet](https://transcan.eu/output-results/funded-projects/bilecanmet.kl): Precision medicine in cholangiocarcinoma: accurate tools for early detection and identification of PRMT5 as a novel pharmacological target [CAR4PDAC](https://transcan.eu/output-results/funded-projects/car4pdac.kl): Hijacking stroma antigens for CAR-T cell immunotherapy of PDAC [iCC-Strat](https://transcan.eu/output-results/funded-projects/icc-strat.kl): Risk stratification and subtyping of intrahepatic cholangiocarcinoma for early detection of recurrence and response to immuno-therapy [IdeaTMEHCC](https://transcan.eu/output-results/funded-projects/ideatmehcc.kl): Identification of therapeutic targets using HCC DErived organoid Augmented with TME components [MATTO-GBM](https://transcan.eu/output-results/funded-projects/matto-gbm.kl): Multimodality Artificial intelligence open-source Tools for radiation Treatment Optimization in patients with Glioblastoma [NK-4-GBM](https://transcan.eu/output-results/funded-projects/nk-4-gbm.kl): Metabolically optimised NK cell therapies for glioblastoma [PaCaNano](https://transcan.eu/output-results/funded-projects/pacanano.kl): Development of a Pancreatic Cancer drug-Nanocarrier system selectively targeting tumour cells and tumour stroma to overcome treatment failure [PANC-P53](https://transcan.eu/output-results/funded-projects/panc-p53.kl): Innovative peptide- and RNA-based strategies to modulate p53 for pancreatic cancer therapy [PLASTIG](https://transcan.eu/output-results/funded-projects/plastig.kl): Tackling tumor heterogeneity and PLASTIcity as resistance mechanisms in Glioblastoma [PRECEDENCE](https://transcan.eu/output-results/funded-projects/precedence.kl): Genotype matched therapies in intrahepatic cholangiocarcinoma: a multi-pronged strategy for improving efficacy and combating resistance [ReachGLIO](https://transcan.eu/output-results/funded-projects/reachglio.kl): REACHing the heterogeneous vascular landscape of GLIOblastoma with multifunctional nanomedicines [SIMMBAP](https://transcan.eu/output-results/funded-projects/simmbap.kl): Systemic IMMunological determinants of tumor evolution and therapy response in BRCA-mutated pancreatic cancer [T-Plex EAC](https://transcan.eu/output-results/funded-projects/t-plex-eac.kl): T-Plex-Capture: isolation of neoantigen-specific CD8+ T cell receptors for patient-specific immunotherapy in Esophageal AdenoCarcinoma ## Publications [TRANSCAN-3 - 1st Symposium - Abstract Book](https://transcan.eu/news-and-resources/publications/transcan-3-1st-symposium-abstract-book.kl): TRANSCAN-3 - First Symposium - Abstract Book, Riga, Latvia, 19-20 October 2023 ## Fact and figures [Statistics of JTC 2022 funded projects](https://transcan.eu/output-results/fact-and-figures/results-of-jtc-2022.kl): Statistical analysis of the call on “Novel translational approaches to tackle the challenges of hard-to-treat cancers from early diagnosis to therapy” ## Latest News [Preliminary announcement: Upcoming Call JTC 2024](https://transcan.eu/news-and-resources/updates/preliminary-announcement-upcoming-call-jtc-2024.kl): "Combination therapies against cancer: new opportunities for translational research" ## Calls for Proposals [Joint Call (JTC 2024)](https://transcan.eu/funding/calls/joint-call-jtc-2024-.kl): “Combination therapies against cancer: new opportunities for translational research” ## Latest News [TRANSCAN-3 launches its fourth transnational call (JTC 2024)](https://transcan.eu/news-and-resources/updates/transcan-3-launches-its-fourth-transnational-call-jtc-2024-.kl): With the support of 21 funding organisations from 16 different countries, TRANSCAN-3 has launched a call for research proposals on the topic of: [Results of the joint transnational call JTC 2023](https://transcan.eu/news-and-resources/updates/results-of-the-joint-transnational-call-jtc-2023.kl): Thirteen research consortia have been selected to receive a total of almost 17 million euros  ## Funded projects [DC2M-TAEC](https://transcan.eu/output-results/funded-projects/dc2m-taec.kl): Detection, Classification, Characterization and Treatment Monitoring of Tumors by Accessible Epigenetic Classification [EPI_T-ALL](https://transcan.eu/output-results/funded-projects/epi_t-all.kl): Unveiling the Epigenetic Landscape and Therapeutic Implications of Epigenetic Modifiers in Human T-cell Leukemia Initiation and Progression [DICE](https://transcan.eu/output-results/funded-projects/dice.kl): Epigenomic regulation of cancer immunity by dietary intervention [EPILUCAFS](https://transcan.eu/output-results/funded-projects/epilucafs.kl): Chronic stress and immunosuppression in lung cancer: focus on epigenetic drivers in cancer-associated fibroblasts [EPILUNAR](https://transcan.eu/output-results/funded-projects/epilunar.kl): Epigenomic Profiling of Liquid Biopsy and Immunotherapy Resistance in Lung Cancer [EpiNanSarc](https://transcan.eu/output-results/funded-projects/epinansarc.kl): Sarcoma subtyping and stratification using genome-wide epigenetic profiling [EXPLORE-NB](https://transcan.eu/output-results/funded-projects/explore-nb.kl): Exploring the epigenetic neuroblastoma landscape to improve measurable disease  monitoring, disease understanding and personalized treatment [HYDRA](https://transcan.eu/output-results/funded-projects/hydra.kl): Charting the epigenomic trajectory of progression towards metastatic colorectal cancer [EPIPROPER](https://transcan.eu/output-results/funded-projects/epiproper.kl): Identifying EPIgenetic determinants and biomarkers of drug resistance via characterization of PROspective PERsister cells [REACH](https://transcan.eu/output-results/funded-projects/reach.kl): Reversing Epitranscriptomic Alterations for CHemosensitization of Pancreatic Cancer [REACTION](https://transcan.eu/output-results/funded-projects/reaction.kl): Deciphering Epigenetic Biomarkers to Identify Preleukemic Carriers at Risk [SCIE-PANC](https://transcan.eu/output-results/funded-projects/scie-panc.kl): Stromal Compartment and Immune Epigenome spatial networks to counter therapy evasion in PANcreatic Cancer [SPELCASTER](https://transcan.eu/output-results/funded-projects/spelcaster.kl): Standardized Profiling of Epigenetic Loci for decentralized ClAssification of Sinonasal Tumors and idEntification of therapy Response markers ## Fact and figures [Results of the call JTC 2023](https://transcan.eu/output-results/fact-and-figures/results-of-jtc-2023-funded-projects.kl): Overview of the call on “Translational research on cancer epigenetics” ## Publications [TRANSCAN-3 - 2nd Symposium - Abstract Book](https://transcan.eu/news-and-resources/publications/transcan-3-2nd-symposium-abstract-book.kl): TRANSCAN-3 - 2nd Symposium - Abstract Book, Catania Sicily, 8-9 October 2024 ## Latest News [ECRs Workshop: A successful hands-on exercise](https://transcan.eu/news-and-resources/updates/ecrs-workshop-a-successful-hands-on-exercise.kl): The event brought together 17 ECRs from 7 countries and featured four distinguished, high-profile scientific evaluators with extensive experience in the TRANSCAN funding scheme. ## Funded projects [ACCELERATE](https://transcan.eu/output-results/funded-projects/accelerate.kl): FunctionAl preCision mediCinE pLatform for the trEatment of pancReATic cancEr [BePrepared](https://transcan.eu/output-results/funded-projects/beprepared.kl): Building an ex vivo complex tumour microenvironment platform for development of combination therapies and drug resistance studies in head neck cancer [DOPPLER-LC](https://transcan.eu/output-results/funded-projects/doppler-lc.kl): Development Of Patient-derived organoid PLatforms for Evading Resistances in Lung Cancer [GLIO-COMBO](https://transcan.eu/output-results/funded-projects/glio-combo.kl): Targeting tumor heterogeneity in pediatric high-grade gliomas [HAVOC](https://transcan.eu/output-results/funded-projects/havoc.kl): Human avatar on chip for advancing personalized cancer therapies by integrating vascular and immune components in a Tumor-on-Chip model [ioAVATAR](https://transcan.eu/output-results/funded-projects/ioavatar.kl): Immune oncology Drug Discovery & Decision - Advanced ex Vivo Approach To Accelerate Response prediction for combined therapies in ovarian cancer [LUNGOIDS](https://transcan.eu/output-results/funded-projects/lungoids.kl): Subtype-specific Lung Cancer Organoids based on artificial ECM for Precision Oncology: Closing the Gap Between Preclinical Models and Patient Care [MELANOLOCK](https://transcan.eu/output-results/funded-projects/melanolock.kl): Tackling resistance to immunotherapy in advanced melanomas through the inhibition of oncomiRs by Locked Nucleic Acids [METRICs](https://transcan.eu/output-results/funded-projects/metrics.kl): Metabolism/Metagenomics-based strategies for sensitization to Radio- and Immuno- therapy Combinations. [PREDICT-BC](https://transcan.eu/output-results/funded-projects/predict-bc.kl): Patient-derived models for the Research and Evaluation of Discovery and Innovation in Combination Therapies for Biliary tract Cancer [SARAH](https://transcan.eu/output-results/funded-projects/sarah.kl): Search for combinational therapy to target clonal haematopoiesis in solid malignancies [SeqPerGlio](https://transcan.eu/output-results/funded-projects/seqperglio.kl): Intraoperative tumour sequencing for personalized loco-regional drug combination therapy against glioblastoma recurrences [TITAN](https://transcan.eu/output-results/funded-projects/titan.kl): Novel Cancer Therapy: Inducing Double-strand DNA Breaks to Foster Tumour Cell Death, Antigenicity and Immunotherapy Response in New Personalized Models [TOSCANINI](https://transcan.eu/output-results/funded-projects/toscanini.kl): TAD disruption and aberrant expression as leukaemia metabolic vulnerabilities for novel combination therapy tests in a drug screening platform [XPANTHER](https://transcan.eu/output-results/funded-projects/xpanther.kl): Radiothermal-Driven Immune Activation to Tackle Pancreatic Hypoxic Tumours ## Latest News [Results of the joint transnational call JTC 2024](https://transcan.eu/news-and-resources/updates/results-of-the-joint-transnational-call-jtc-2024.kl): 15 international consortia awarded €16.7 million to advance combination therapies against cancer ## Publications [TRANSCAN-3 - 3rd Symposium - Abstract Book](https://transcan.eu/news-and-resources/publications/transcan-3-3rd-symposium-abstract-book.kl): TRANSCAN-3 - 3rd Symposium - Abstract Book, Milan, Italy, 28-29 October 2025 ## Fact and figures [Results of the call JTC 2024](https://transcan.eu/output-results/fact-and-figures/results-of-the-call-jtc-2024.kl): Overview of the call on “Combination therapies against cancer: new opportunities for translational research.” ## Latest News [TRANSCAN‑4 — a new initiative:](https://transcan.eu/news-and-resources/updates/preliminary-announcement-upcoming-call-jtc-2026.kl): Pre-announcement of the First Joint Transnational Call (JTC 2026)    ## Calls for Proposals [Joint Call (JTC 2026)](https://transcan.eu/funding/calls/joint-call-jtc-2026-.kl): "Translational Research on Cancer Metabolism: Multidisciplinary Approaches for Diagnosis and Treatment" ## Latest News [TRANSCAN-4 first JTC is now open!](https://transcan.eu/news-and-resources/updates/the-transcan-4-joint-transnational-call-jtc-2026-is-officially-launched-today-.kl): The TRANSCAN-4 first Joint Transnational Call is officially launched today! [TRANSCAN-4](https://transcan.eu/news-and-resources/updates/future-home-of-transcan-4.kl): TRANSCAN-4 will further advance the strong legacy of previous TRANSCAN initiatives